Mezigodomide-Based Regimen Delivers Significant Survival Benefits in R/R Multiple Myeloma - OncLive

Mezigodomide-Based Regimen Delivers Significant Survival Benefits in R/R Multiple Myeloma    OncLive #ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successor    Endpoints News ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study    Fierce Biotech Bristol Myers drug delays myeloma progression in hard to treat patients    Yahoo At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer    statnews.com

Original source: Google News